Currently, Glenn Goddard is Executive VP, Chief Financial & Accounting Officer at Intellia Therapeutics, Inc.
He previously was Senior Vice President-Finance of Agios Pharmaceuticals, Inc., Chief Financial Officer of Generation Bio Co., Controller of ImmunoGen, Inc., Vice President-Finance for Archemix Corp., Principal at Ernst & Young LLP and Principal at Feeley & Driscoll PC.
He received an undergraduate degree from Bentley University.
|03/01/2022||12,720||Award at $0 per share.||0|
|01/01/2022||1,013||Disposition at $112.24 per share.||113,700|
|01/01/2022||3,062||Derivative/Non-derivative trans. at $0 per share.||0|
|09/07/2021||3,482||Disposition at $180.12 per share.||627,178|
|09/07/2021||3,482||Derivative/Non-derivative trans. at $14.58 per share.||50,767|
|08/31/2021||24,800||Disposition at $160.22 per share.||3,973,456|
|08/31/2021||1,817||Derivative/Non-derivative trans. at $14.58 per share.||26,491|
|08/31/2021||22,983||Derivative/Non-derivative trans. at $19.27 per share.||442,882|
|08/30/2021||300||Disposition at $160.84 per share.||48,252|
|08/30/2021||300||Disposition at $159.53 per share.||47,859|
|08/30/2021||300||Disposition at $158.42 per share.||47,526|
|08/30/2021||496||Disposition at $157.33 per share.||78,036|
|08/30/2021||300||Disposition at $156.1 per share.||46,830|
|08/30/2021||1,700||Disposition at $155.29 per share.||263,993|
|08/30/2021||1,100||Disposition at $154.29 per share.||169,719|
|08/30/2021||704||Disposition at $153.22 per share.||107,867|
|08/30/2021||5,200||Derivative/Non-derivative trans. at $19.27 per share.||100,204|
|08/05/2021||530||Disposition at $152.13 per share.||80,629|
|08/05/2021||9,568||Disposition at $151.41 per share.||1,448,691|
|08/05/2021||9,902||Disposition at $150.65 per share.||1,491,737|
|08/05/2021||20,000||Derivative/Non-derivative trans. at $19.27 per share.||385,400|